Cytokinetics (CYTK) said Tuesday it is enrolling patients in a phase 3 trial designed to evaluate the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
The trial is expected to randomize about 1,800 patients on a 1:1 basis to receive omecamtiv mecarbil or placebo, the company said.
Cytokinetics is conducting the trial in collaboration with the Duke Clinical Research Institute.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments